Dr. Gaggar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
303 Velocity Way
Foster City, CA 94404
Education & Training
University of California (San Francisco)Fellowship, Infectious Disease, 2008 - 2011- University of California (San Francisco)Residency, Internal Medicine, 2006 - 2010
University of Washington School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2014
Clinical Trials
Publications & Presentations
PubMed
- Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation.Zhi Ming Xu, Gnimah Eva Gnouamozi, Sina Rüeger, Patrick R Shea, Maria Buti
American Journal of Human Genetics. 2024-06-06 - 1 citationsSafety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.Harry L Janssen, Young-Suk Lim, Hyung Joon Kim, Leonard Sowah, Cheng-Hao Tseng
JHEP Reports. 2024-02-01 - 11 citationsPhenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.Marzia Rossi, Andrea Vecchi, Camilla Tiezzi, Valeria Barili, Paola Fisicaro
Gut. 2023-11-01
Journal Articles
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
Trial Finds Drug Safe and Effective in Treating Hep-C During PregnancyJuly 28th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
